Cathomas, R., Crabb, S., Kenner, H., Mark, M., Rothermundt, C., Elliott, T., Winterhalder, R., Von Burg, P., Berardi Vilei, S., Hayoz, S., Rauch, D., Roggero, E., Stenner, F., Berthold, D., Erdmann, A., Fischer, N., Manetsch, G., & Gillessen, S. (n.d.). 2500 Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11). European journal of cancer, 51(3), S473–. http://access.bl.uk/ark:/81055/vdc_100050954837.0x00002c